Skip to Main Content

Paper Details

Cardiorenal outcomes with ertugliflozin assessed according to baseline glucose-lowering agent: An analysis from VERTIS CV.
Diabetes Obes Metab
5
2022
Author NameAffiliation
Christopher P CannonBrigham and Women's Hospital, Harvard Medical School
David Z I CherneyUniversity of Toronto
  • 1 - 2

Datasets

Release 1.2